Teply BA, et al. - Authors perform this study to assess the utility of bipolar androgen therapy [BAT] in patients with metastatic castration-resistant prostate cancer that progressed after enzalutamide. Findings suggest that BAT is a safe therapy. The therapy resulted in responses in asymptomatic men with metastatic castration-resistant prostate cancer and also resensitisation to enzalutamide in most patients undergoing rechallenge. They identify the necessity for further studies with BAT to assess the potential clinical role for BAT in the management of metastatic castration-resistant prostate cancer and the optimal strategy for sequencing between androgen and antiandrogen therapies in metastatic castration-resistant prostate cancer to maximise therapeutic benefit to patients.